Sponsored Content
Thomas Lingelbach
Austro-French Vaccine Company Valneva's Covid-19 Jab under EU Review
The EU's medicines agency EMA launched an accelerated review of a Covid-19 vaccine by Austro-French biotech firm Valneva. Recently the European Commission agreed to buy as many as 60 million doses of its Covid-19 vaccine. The deal would allow EU member states to purchase almost 27 million doses from Valneva in 2022, and an additional 33 million in 2023.
December 2, 2021
Intercell Plans to Achieve Turnaround in 2014
The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.
February 6, 2012
Intercell Looking for Private Equity Shareholder
According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.
September 27, 2011
Intercell Successfully Completes Vaccine Study in India
The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.
September 16, 2011
Intercell Is Looking for Financial Investors
The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.
July 19, 2011
Intercell: “We Will Stabilize Our Share Price”
The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.
June 21, 2011
Intercell to Cut Jobs and Research Budget
The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.
June 8, 2011
Intercell: Sale Is No Longer Ruled Out
The new CEO of the Austrian pharmaceutical company, Thomas Lingelbach intends to implement a new strategy for the company. A sale is possible.
May 11, 2011
Lingelbach New CEO for Intercell
Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed.
May 5, 2011
Fast News Search
